Related Experiment Video
Updated: Aug 15, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Recent developments in therapeutic cancer vaccines
Michael A Morse1, Stephen Chui, Amy Hobeika
1Duke University Medical Center, Durham, North Carolina 27710, USA. michael.morse@duke.edu
Abstract:
Therapeutic cancer vaccines are being developed with the intention of treating existing tumors or preventing tumor recurrence. While the results of clinical trials, predominantly in the metastatic setting have been sobering, the central hypothesis of active immunotherapy i.e. that the human immune system can be activated to recognize and destroy tumor cells, remains a viable one. We believe that a fundamental shift in how clinical trials are performed, and what concepts they test is required to make meaningful strides towards future clinical use of cancer vaccines. First, we must reappraise whether the metastatic setting is the appropriate arena to test these agents. Second, we must arrive at a consensus on the most important biologic endpoints and rapidly test vaccines for their ability to achieve these endpoints. Third, we need to expend more effort on understanding how to manipulate the immune system beyond the initial stimulation provided by a vaccine. Fourth, in order to permit comparison of results across different studies, it would be helpful to narrow down the large number of vaccine platforms. We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers.
Insights
Therapeutic cancer vaccines show promise, but clinical trials need a strategic shift. Future research should focus on optimizing vaccine platforms and understanding immune system manipulation for better cancer treatment and prevention.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Therapeutic cancer vaccines aim to treat existing tumors and prevent recurrence.
- Current clinical trial results, especially in metastatic settings, have been disappointing.
- The core principle of active immunotherapy—harnessing the immune system against cancer—remains valid.
Purpose of the Study:
- To critically evaluate the current state of therapeutic cancer vaccine development.
- To propose essential changes in clinical trial design and focus for future cancer vaccine research.
- To discuss the potential of cancer vaccines in treating and preventing various cancers.
Main Methods:
- Review of current therapeutic cancer vaccine development and clinical trial outcomes.
- Analysis of the limitations and challenges in existing research paradigms.
- Discussion of strategic shifts needed for advancing cancer vaccine efficacy.
Main Results:
- The hypothesis that the immune system can be activated to fight cancer is scientifically sound.
- Existing trial designs, particularly in the metastatic setting, may not be optimal for demonstrating vaccine efficacy.
- Significant improvements are needed in defining biologic endpoints and understanding post-vaccination immune modulation.
Conclusions:
- A fundamental re-evaluation of clinical trial methodologies is crucial for the successful development of cancer vaccines.
- Future research must prioritize consensus on key biologic endpoints, explore immune system manipulation beyond initial stimulation, and standardize vaccine platforms.
- These strategic adjustments are vital for realizing the clinical potential of cancer vaccines in treating and preventing cancer.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...